We hereby announce that we have received an update from our licensee, Asahi Kasei Pharma Corporation (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Yoshikazu Aoki; hereinafter "Asahi Kasei Pharma"), regarding the latest status of the P2X7 receptor antagonist (compound code: AK1780/RQ-00466479/LY3857210; hereinafter referred to as "the Compound").
On October 30, 2025 (local time), the pipeline of Eli Lilly and Company (Headquarters: Indianapolis, Indiana, USA; hereinafter "Lilly"), the licensee of Asahi Kasei Pharma, was updated, and development of this compound for the target disease "Pain" was removed. However, this does not signify the termination of Lilly's entire P2X7 program. The license agreement between Asahi Kasei Pharma and Lilly remains in full force and effect, and future development plan is under discussion by Lilly.
We will continue to monitor the latest developments through Asahi Kasei Pharma and will promptly provide updates should any changes occur.
We will continue to strengthen our collaboration with Asahi Kasei Pharma and persist in our challenge to realize innovative drug discovery. We appreciate your continued support and understanding.